Note 16 - Customer Concentration

12 Months Ended

Dec. 31, 2011

Concentration Risk Disclosure [Text Block]

16. Customer Concentration

The percentage of total revenue earned from licensees net sales, which individually accounted for 10% or more of our total revenues:

	Year Ended December 31,
	2011			2010			2009
Licensees
Genentech, Inc. (Genentech)		86	%		86	%		71	%
Elan Corporation, Plc (Elan)		12	%		10	%		9	%
MedImmune, Inc. (MedImmune)		0	%		0	%		13	%

Total revenues by geographic area are based on the country of domicile of the counterparty to the agreement:

	Year Ended December 31,
(In thousands)	2011		2010		2009
United States	$	137,269	$	130,070	$	154,706
Europe		224,472		213,677		160,743
Other		300		1,228		2,735
Total revenues	$	362,041	$	344,975	$	318,184